Use of CDC2 from etoposide-treated cells as substrate to assay CDC25 phosphatase activity

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1241-1244

  Cans, Christophe ^a   Sert, Valerie ^b   De Rycke, Jean ^b   Baldin, Véronique ^a   Ducommun, Bernard ^a  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b CEMAGREF   (France)

Author keywords

CDC25 phosphatase; Cell cycle; Cyclin dependent kinase; Etoposide

Indexed keywords

ANTIMITOTIC AGENT; CYCLIN DEPENDENT KINASE; ETOPOSIDE; PHOSPHATASE; PROTEIN KINASE; RECOMBINANT ENZYME; TYROSINE;

ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DEPHOSPHORYLATION; DNA DAMAGE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

CDC2 PROTEIN KINASE; CDC25 PHOSPHATASE; CELL CYCLE PROTEINS; ETOPOSIDE; HELA CELLS; HUMANS; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; TYROSINE;

EID: 0032997651     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995.
2. Jessus C and Ozon R: In: Progress in Cell Cycle Research, Vol. 1, pp. 215-228 (Meijer L, Guidet S and Tung HYL, Eds.) Plenum Press, New York, USA, 1995.
3. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H and Elledge S: Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through cdc25. 277: 1497-1501, 1997.
4. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H: Mitotic and G2 checkpoint control: regulation of 14.3.3 protein binding by phosphorylation of CDC25C on Serine-216. Science 277: 1501-1505, 1997.
5. Galaktionov K, Lee AK, Eckstein J, Dràetta G, Meckler J, Loda M and Beach D: Cdc25 phosphatases as potential human oncogenes. Science 269: 1575-1577, 1995.
6. Rice R, Rusnak JM, Yokokawa F, Yokokawa S, Messner DJ, Boynton AL, Wipf P and Lazo JS: A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry 36: 15965-15974, 1997.
7. Galaktionov K and Beach D: Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cycling. Cell 67: 1181-1194, 1991.
8. Dunphy W and Kumagai A: The cdc25 protein contains an intrinsic phosphatase activity. Cell 67: 189-196, 1991.
9. Gottlin EB, Xu X, Epstein DM, Burke SP, Eckstein JW, Ballou DP and Dixon JE: Kinetic analysis of the catalytic donain of human CXDC25B. J Biol Chem 271: 27445-27449, 1996.
10. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biocheml 58: 351-375, 1989.
11. Baldin V, Cans C, Superti-Furga G and Ducommun B: Alternative splicing of the human CDC25B tyrosine phoshatase. Possible implications for growth control? Oncogene 14: 2485-2495, 1997.
12. Brizuela L, Draetta G and Beach D: p13suc1 acts in the fission yeast cell division cycle as a component of the p34cdc2 protein kinase. EMBO J 6: 3507-3514, 1987.
13. Roberge M, Th'ng J, Hamaguchi J and Bradbury EM: The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, hitone H1 and H3 phosphorylation and chromosome condensation in G2 phase and mitotic BHK cells. J Cell Biol 111: 1753-1762, 1990.
14. Clark JM and Gabrielli BG: Production of a soluble cyclin B/cdc2 substrate for cdc25 phosphatase. Anal Biochem 254: 231-235, 1997.